Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZM-PI05 |
Synonyms | |
Therapy Description |
ZM-PI05 is a proteolysis-targeting chimera (PROTAC) targeting PI3K, which potentially degrades Pik3ca and Pik3r1 and inhibits proliferation and tumor growth (PMID: 38986734). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZM-PI05 | ZM PI05|ZMPI05 | PI3K Inhibitor (Pan) 42 | ZM-PI05 is a proteolysis-targeting chimera (PROTAC) targeting PI3K, which potentially degrades Pik3ca and Pik3r1 and inhibits proliferation and tumor growth (PMID: 38986734). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | breast cancer | sensitive | ZM-PI05 | Preclinical - Cell culture | Actionable | In a preclinical study, ZM-PI05 decreased viability of a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 38986734). | 38986734 |
PIK3CA H1047R | Her2-receptor positive breast cancer | sensitive | ZM-PI05 | Preclinical - Cell culture | Actionable | In a preclinical study, ZM-PI05 induced cell cycle arrest and decreased viability of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 38986734). | 38986734 |
PIK3CA C420R | Her2-receptor positive breast cancer | sensitive | ZM-PI05 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ZM-PI05 induced cell cycle arrest and decreased viability of an ERBB2 (HER2)-positive breast cancer cell line harboring PIK3CA C420R in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38986734). | 38986734 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|